Bioequivalence of the 4-mg Oral Granules and Chewable Tablet Formulations of Montelukast

Archives of Drug Information

Volumn 3, Issue 2, 2010, Pages 37-43

  Knorr, Barbara ^a   Hartford, Alan ^b   Li, Xiujiang ^a   Yang, Amy Yifan ^a   Noonan, Gertrude ^a   Migoya, Elizabeth ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Agensys Inc   (United States)

Author keywords

Bioequivalence; Montelukast; Pediatric Formulations; Pharmacokinetics

Indexed keywords

MONTELUKAST;

ADULT; ARTICLE; BIOEQUIVALENCE; CHEWABLE TABLET; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; FOOD DRUG INTERACTION; HUMAN; LIPID DIET; MALE; OPEN STUDY; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION;

EID: 77954364630     PISSN: None     EISSN: 17535174     Source Type: Journal    
DOI: 10.1111/j.1753-5174.2010.00029.x     Document Type: Article

References (7)

1. Migoya E, Kearns GL, Hartford A, Zhao J, van Adelsberg J, Tozzi CA. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. J Clin Pharmacol 2004, 44:487-94.
2. Knorr B, Nguyen HH, Kearns GL, Villaran C, Boza ML, Reiss TF. Montelukast dose selection in children ages 2 to 5 years: Comparison of population pharmacokinetics between children and adults. J Clin Pharmacol 2001, 41:612-9.
3. Knorr B, Larson P, Nguyen HH, Holland S, Reiss TF, Chervinsky P. Montelukast dose selection in 6- to 14-year-olds: Comparison of single-dose pharmacokinetics in children and adults. J Clin Pharmacol 1999, 39:786-93.
4. Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug products-General considerations. 2000, US Department of Health and Human Services
5. Evaluation of Medicines for Human Use, Committee for Proprietary Medicinal Products (CPMP) Note for guidance on the investigation of bioavailability and bioequivalence. 2000, European Agency for the Evaluation of Medicinal Products
6. Amin RD, Cheng H, Rogers JD. Determination of MK-0476 in human plasma by liquid chromatography. J Pharm Biomed Anal 1995, 40:277-80.
7. Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for industry: Food-effect bioavailability and fed bioequivalence studies. 2002, US Department of Health and Human Services